Schedule 13D Amendment No. 3

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO

13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a)

(Amendment No. 3)1

Celldex Therapeutics, Inc.

(Name of Issuer)

Common Stock par value $0.001 per share

(Title Class of Securities)

15117B103

(CUSIP Number)

Bristol-Myers Squibb Company

345 Park Avenue

New York, New York 10154

(212) 546-4000

Attn: General Counsel

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

November 23, 2009

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box  ¨.

Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

 

1  

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP No. 15117B103    13D    Page 2 of 12

 

  1   

NAME OF REPORTING PERSON

Medarex, Inc.

 

S.S. OR I.R.S. IDENTIFICATION OF ABOVE PERSON

IRS Identification Number 22-2822175

  2  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)  ¨        (b)  ¨

 

  3  

SEC USE ONLY

 

  4  

SOURCE OF FUNDS*

 

    AF, OO

  5  

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)    ¨

 

  6  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

    Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

     7    

SOLE VOTING POWER

 

    0

     8   

SHARED VOTING POWER

 

    2,889,223

     9   

SOLE DISPOSITIVE POWER

 

    0

   10   

SHARED DISPOSITIVE POWER

 

    2,889,223

11

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

    2,889,223

12

 

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*    ¨

 

13

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

 

    9.14%

14

 

TYPE OF REPORTING PERSON

 

    CO

*SEE INSTRUCTION BEFORE FILLING OUT


CUSIP No. 15117B103    13D    Page 3 of 12

 

  15   

NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION OF ABOVE PERSON

 

Bristol-Myers Squibb Company

IRS Identification Number 22-0790350

  16  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)  ¨        (b)  ¨

 

  17  

SEC USE ONLY

 

  18  

SOURCE OF FUNDS*

 

    AF. OO

  19  

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)    x

 

  20  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

    Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

     21    

SOLE VOTING POWER

 

    0

     22   

SHARED VOTING POWER

 

    2,889,223

     23   

SOLE DISPOSITIVE POWER

 

    0

     24   

SHARED DISPOSITIVE POWER

 

    2,889,223

25

 

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

    2,889,223

26

 

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*    ¨

 

27

 

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

 

    9.14%

28

 

TYPE OF REPORTING PERSON

 

    CO

 


CUSIP No. 15117B103    13D    Page 4 of 12

 

This Amendment No. 3 (the “Schedule 13D/A”) amends the Statement on Schedule 13D (the “Schedule 13D”) filed with the Securities and Exchange Commission (the “SEC”) on March 17, 2008 by Medarex, Inc. (“Medarex”), as amended. This Schedule 13D/A is also an initial filing by Bristol-Myers Squibb Company (“Bristol-Myers” and together with Medarex , the “Reporting Persons”).

 

Item 1. Security and Issuer

This Schedule 13D/A relates to the Common Stock, par value $0.001 per share (the “Common Stock”), of Celldex Therapeutics, Inc., a Delaware corporation (“Celldex”), formerly known as AVANT Immunotherapeutics, Inc. (“AVANT”). Celldex’s principal executive offices are located at 119 Fourth Avenue, Needham, Massachusetts 02494.

 

Item 2. Identity and Background

Medarex, a New Jersey corporation, is a biopharmaceutical company focused on the discovery, development and commercialization of fully human antibody-based therapeutic product candidates for the treatment of a wide range of diseases, including cancer, inflammation, autoimmune disorders and other life-threatening and debilitating diseases. Medarex’s principal place of business and executive offices are located at Route 206 & Provinceline Road, Princeton, New Jersey 08540.

This Schedule 13D/A is also an initial filing by Bristol-Myers, a Delaware corporation, with its principal executive offices at 345 Park Avenue, New York, New York 10154. Bristol-Myers may be deemed to be the beneficial owner of the Common Stock owned by Medarex by virtue of its acquisition of 100% of the voting shares of Medarex by means of a merger effective September 1, 2009. Bristol-Myers is principally engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and related health care products.

The name, principal occupation or employment and principal business address and citizenship of each director and executive officer of the Reporting Persons are as set forth on Schedule A.

During the past five years, neither Medarex, nor, to Medarex’s knowledge, any of the directors and executive officers of Medarex listed in Schedule A (1) has been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors) or (2) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding were or are subject to a judgment, decree or final order enjoining future violations of, or prohibited or mandating activities subject to, U.S. federal or state securities laws or finding any violations with respect to such laws.

On June 11, 2007, Bristol-Myers resolved an investigation by the Antitrust Division of the U.S. Department of Justice (“DOJ”) into the proposed settlement of the PLAVIX* patent litigation by pleading guilty to two counts of violating 18 U.S.C Sec. 1001 (relating to false statements to a government agency) (the Plea) and paid a fine of $1 million. As part of the Plea, Bristol-Myers acknowledged that a former Bristol-Myers senior executive made oral representations to Apotex for the purpose of causing Apotex to conclude that Bristol-Myers would not launch an authorized generic in the event that the parties reached a final revised settlement agreement. Those representations included the former senior executive’s statement that he expected to oppose personally the launch of an authorized generic in the future, his statement that he expected to advocate against such a launch, and his implied suggestion that Bristol-Myers’s former Chief Executive Officer (CEO) shared his views. The failure to disclose this information to the FTC in connection with the FTC’s review of the Modified Agreement operated as incomplete and therefore false statements to the FTC. Bristol-Myers also acknowledged its responsibility for the conduct of the former senior executive.


CUSIP No. 15117B103    13D    Page 5 of 12

 

In addition, on September 28, 2007, Bristol-Myers, the DOJ and the Office of the U.S. Attorney for the District of Massachusetts finalized an agreement (the “Settlement Agreement”) in principle to settle several investigations involving Bristol-Myers’s drug pricing, sales and marketing activities. The Settlement Agreement, which provided for a civil resolution, resolved matters that had been actively investigated by and discussed with the DOJ and the U.S. Attorney for the District of Massachusetts over a number of years, including matters relating to (a) the pricing for certain products sold several years ago by a subsidiary of Bristol-Myers, which had been reimbursed by governmental health care programs; (b) financial relationships between that subsidiary and certain customers and other entities; (c) certain consulting programs; (d) the promotion of ABILIFY* for unapproved indications; (e) the calculation of certain Medicaid rebates for SERZONE (nefazodone hydrochloride); and (f) the pricing for certain of the Bristol-Myers’s products reimbursed by governmental health care programs. There were no criminal charges against Bristol-Myers with respect to those matters. Pursuant to the Settlement Agreement, Bristol-Myers agreed to pay $499 million plus interest to resolve the Federal and State claims, resulting in a total amount of approximately $516 million as of the settlement date.

During the past five years, except as discussed above, neither Bristol-Myers, nor, to Bristol-Myers’s knowledge, any of the directors and executive officers of Bristol-Myers listed in Schedule A (1) has been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors) or (2) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding were or are subject to a judgment, decree or final order enjoining future violations of, or prohibited or mandating activities subject to, U.S. federal or state securities laws or finding any violations with respect to such laws.

 

Item 3. Source and Amount of Funds or Other Consideration

The shares of Common Stock owned by Medarex were acquired by Medarex as the result of the merger of AVANT and Celldex, in March of 2008. Bristol Myers acquired Medarex by means of the merger described in Item 2 above.

 

Item 4. Purpose of Transaction

Following the acquisition of Medarex by Bristol-Myers, the Reporting Persons reevaluated Medarex’s investment in Celldex. Medarex expects to make additional sales of the Common Stock reported in this Schedule 13D/A over time as market conditions permit in the open market or in private transactions.

Except as described above, the Reporting Persons do not have any plans or proposals which relate to or would result in any of the actions listed in Item 4 of Schedule 13D. Although there is no present intention to do so, the Reporting Persons and/or any person named on Schedule A attached hereto may decide to discontinue any such sales or make purchases in the future either in the open market or in private transactions, subject to its or their evaluation of the Celldex’s business, prospects and financial condition, the market for the Common Stock, other opportunities available to the Reporting Persons or any person named on Schedule A attached hereto, prospects for the respective businesses of the Reporting Persons, general economic conditions, money and stock market conditions and other future developments.


CUSIP No. 15117B103    13D    Page 6 of 12

 

Item 5. Interest in Securities of the Issuer

The Reporting Persons beneficially own 2,889,223 shares of the Common Stock (9.14% of the Celldex’s issued and outstanding shares of Common Stock, based upon information set forth in the Celldex’s Form 10-Q for the quarter ended September 30, 2009, indicating that 31,602,188 shares of Common Stock were issued and outstanding on September 30, 2009). The Reporting Persons share voting and investment power with regard to all 2,889,223 shares of Common Stock that they beneficially own. Except as reported in Schedule A, none of the persons listed therein, to the knowledge of the Reporting Persons, is the beneficial owner of any shares of the Common Stock of Celldex.

The following dispositions of Common Stock were effected on the following dates and at the following prices in the past 60 days:

 

Date

   No. of Shares    Price
Per Share*

November 23, 2009

   49,867    $ 4.92

November 24, 2009

   21,758    $ 4.75

 

Item 6 Contracts, Arrangements, Understandings or Relationships with respect to Securities of the Issuer

Not Applicable.

 

Item 7. Material to be Filed as Exhibits

Exhibit 1 Joint Filing Agreement


CUSIP No. 15117B103    13D    Page 7 of 12

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

      MEDAREX, INC.
Date:  

November 25, 2009

    By:  

/s/    Sonia Vora        

      Name:   Sonia Vora
      Title:   Secretary
      BRISTOL-MYERS SQUIBB COMPANY
Date:  

November 25, 2009

    By:  

/s/    Sandra Leung        

      Name:   Sandra Leung
      Title:   Senior Vice President and General Counsel


CUSIP No. 15117B103    13D    Page 8 of 12

 

SCHEDULE A

EXECUTIVE OFFICERS AND DIRECTORS OF MEDAREX, INC.

 

David Bonk    Director and Officer    Route 206 & Provinceline Road, Princeton NJ 08540    USA  

Director, Vice President,

Vice President & Associate General

Counsel at Bristol-Myers Squibb

Company

Joseph Campisi    Officer    Route 206 & Provinceline Road, Princeton NJ 08540    USA  

Vice President

Vice President & Senior

Counsel, Corporate Development

at Bristol-Myers Squibb

Company

Jeffrey Galik    Director and Officer    Route 206 & Provinceline Road, Princeton NJ 08540    USA  

Director and Treasurer

Treasurer at Bristol-Myers Squibb

Company

Dr. Jeremy Levin    Director and Officer    Route 206 & Provinceline Road, Princeton NJ 08540   

USA,

Great Britain

 

Director, President

Senior Vice President Strategic Transactions at Bristol-Myers Squibb

Company

Sonia Vora    Officer    Route 206 & Provinceline Road, Princeton NJ 08540    USA  

Secretary

Senior Counsel and Assistant Corporate

Secretary at Bristol-Myers Squibb

Company


CUSIP No. 15117B103    13D    Page 9 of 12

 

EXECUTIVE OFFICERS AND DIRECTORS OF BRISTOL-MYERS SQUIBB COMPANY

 

Name

  

Position with Bristol-

Myers Squibb

Company

  

Principal Business Address

  

Citizenship

  

Present Principal
Occupation

Lamberto Andreotti    Executive Officer and Director    Bristol-Myers Squibb Company, 345 Park Avenue, New York, NY 10154    Italy    Director, President and Chief Operating Officer
Joseph Caldarella    Executive Officer    Bristol-Myers Squibb Company, Route 206 & Provinceline Road, Lawrenceville, NJ 08543    USA    Vice President and Corporate Controller
Beatrice Cazala   

Executive Officer

  

Bristol-Myers Squibb Company, 3 rue Joseph Monier, BP 325

Rueil-Malmaison Cedex

92506, France

  

France

  

President, Global Commercialization and President, Europe

Lewis B. Campbell    Director    Bristol-Myers Squibb Company, 345 Park Avenue, New York, NY 10154    USA    Chairman of the Board of Directors, President and Chief Executive Officer of Textron Inc.
John E. Celentano    Executive Officer    Bristol-Myers Squibb Company, 345 Park Avenue, New York, NY 10154    USA    President, Emerging Markets and Asia Pacific
James M. Cornelius    Executive Officer and Director    Bristol-Myers Squibb Company, 345 Park Avenue, New York, NY 10154    USA    Chairman of the Board of Directors and Chief Executive Officer
Brian Daniels    Executive Officer    Bristol-Myers Squibb Company, Route 206 & Provinceline Road, Lawrenceville, NJ 08543    USA    Senior Vice President, Global Development and Medical Affairs, Research and Development
Louis J. Freeh    Director    Bristol-Myers Squibb Company, 345 Park Avenue, New York, NY 10154    USA    President of Freeh Group International Solutions, LLC and Managing Partner Freeh Sullivan Sporkin, LLP


CUSIP No. 15117B103    13D    Page 10 of 12

 

Laurie H. Glimcher, M.D.    Director    Bristol-Myers Squibb Company, 345 Park Avenue, New York, NY 10154    USA    Irene Heinz Given Professor of Immunology at the Harvard School of Public Health and Professor of Medicine at Harvard Medical School
Michael Grobstein    Director    Bristol-Myers Squibb Company, 345 Park Avenue, New York, NY 10154    USA    Retired
Anthony C. Hooper    Executive Officer    Bristol-Myers Squibb Company, Route 206 & Provinceline Road, Princeton, NJ 08540    USA    President, Americas
Jean-Marc Huet    Executive Officer    Bristol-Myers Squibb Company, Route 206 & Provinceline Road, Lawrenceville, NJ 08543    Netherlands    Executive Vice President and Chief Financial Officer
Leif Johansson    Director    Bristol-Myers Squibb Company, 345 Park Avenue, New York, NY 10154    Sweden    President of AB Volvo and Chief Executive Officer of the Volvo Group
Alan J. Lacy    Director    Bristol-Myers Squibb Company, 345 Park Avenue, New York, NY 10154    USA    Senior Advisor to Oak Hill Capital Partners, L.P.
Sandra Leung    Executive Officer    Bristol-Myers Squibb Company, 345 Park Avenue, New York, NY 10154    USA    Senior Vice President, General Counsel and Corporate Secretary
Anthony A. McBride    Executive Officer    Bristol-Myers Squibb Company, Route 206 & Provinceline Road, Lawrenceville, NJ 08543    USA    Senior Vice President, Human Resources
Carlo de Notaristefani    Executive Officer    Bristol-Myers Squibb Company, 345 Park Avenue, New York, NY 10154    Italy    President, Technical Operations and Global Support Functions
Vicki L. Sato, Ph.D.    Director    Bristol-Myers Squibb Company, 345 Park Avenue, New York, NY 10154    USA    Professor of management practice at the Harvard Business School and Professor of molecular and cell biology at Harvard University


CUSIP No. 15117B103    13D    Page 11 of 12

 

Elliott Sigal, M.D., Ph.D.    Executive Officer    Bristol-Myers Squibb Company, 345 Park Avenue, New York, NY 10154    USA    Executive Vice President, Chief Scientific Officer and President, Research and Development
Togo D. West, Jr.    Director    Bristol-Myers Squibb Company, 345 Park Avenue, New York, NY 10154    USA    Chairman of the Board of Directors of TLI Leadership Group and Chairman of the Board of Directors of Noblis, Inc.
R. Sanders Williams, M.D.    Director    Bristol-Myers Squibb Company, 345 Park Avenue, New York, NY 10154    USA    Senior Vice Chancellor for Academic Affairs at Duke University Medical Center
Robert T. Zito    Executive Officer    Bristol-Myers Squibb Company, 345 Park Avenue, New York, NY 10154    USA    Senior Vice President, Corporate and Business Communications and Chief Communications Officer
Joint Filing Agreement
CUSIP No. 15117B103    13D    Page 1 2 of 12

 

Exhibit 1

JOINT FILING AGREEMENT

JOINT FILING AGREEMENT, dated as of the 25th day of November, 2009, among Bristol-Myers Squibb Company and Medarex Inc. (together, the “Reporting Persons”).

WHEREAS, pursuant to Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the parties hereto desire to satisfy any filing obligation under Section 13(d) of the Exchange Act by a single joint filing;

NOW, THEREFORE, in consideration of the premises and the mutual covenants herein contained, the Reporting Persons hereby agree and represent as follows:

 

  1. Schedule 13D/A with respect to the Common Stock, par value $0.001 per share, of Celldex Therapeutics, Inc (to which this Joint Filing Agreement is an exhibit) is filed on behalf of each of the Reporting Persons.

 

  2. Each of the Reporting Persons is responsible for the timely filing of Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such Person contained therein, provided that each such Person is not responsible for the completeness or accuracy of the information concerning any of the other Reporting Persons, unless such Person knows or has reason to believe that such information is inaccurate.

IN WITNESS WHEREOF, the undersigned have caused this Joint Filing Agreement to be duly executed and delivered as of the date first above written.

 

    MEDAREX, INC.
Date:  

November 25, 2009

  By:  

/s/ Sonia Vora

      Name:   Sonia Vora
      Title:   Secretary
    BRISTOL-MYERS SQUIBB COMPANY
Date:  

November 25, 2009

  By:  

/s/ Sandra Leung

      Name:   Sandra Leung
      Title:   Senior Vice President and General Counsel